Followers | 14 |
Posts | 807 |
Boards Moderated | 0 |
Alias Born | 04/24/2009 |
Wednesday, July 23, 2014 11:10:42 AM
Oncology agreement with AstraZeneca expanded A second, expanded agreement with AstraZeneca in the field of
cancer medicine using Starpharma’s proprietary DEP™
technology is a strong validation of the interest in the Company’s
drug delivery technology. The agreement follows an earlier
agreement with AstraZeneca to access Starpharma’s delivery
technology. The new agreement will see the application of
Starpharma’s technology to a cancer drug, from AstraZeneca’s
pipeline.
“As a leading discovery-led company this alliance represents
an exciting collaboration with an Australian-based company to
combine the oncology treatments of tomorrow that AstraZeneca is
developing using innovative delivery mechanisms,” said Mark
Fladrich, Managing Director, AstraZeneca Australia.
Under the new agreement, AstraZeneca will provide funding
for a pre-clinical stage cancer research program to be
conducted jointly.
http://www.starpharma.com/assets/asxannouncements/140612_Shareholder_Update_JUNE_1.pdf
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM